December Newsletter Favorite Highlights from the month |
|
|
Announcements: IAES has added a new page on our website for our Spanish speaking members. ________________ Anuncios: IAES ha agregado una nueva página en nuestro sitio web para nuestros miembros de habla hispana |
|
|
encefalitis autoinmuneencefalitis autoinmune información, tratamiento, diagnóstico, síntomas, videos, anti-NMDAr |
|
|
Amobi Okoye's journey anything but typical Former Texans defensive tackle Amobi Okoye contracted a rare form of Autoimmune Encephalitis that nearly claimed his life, and now he's trying to make a comeback to the NFL. |
|
|
145 Days | Amobi Okoye"What are you talking about? It's like ... March." We're going back and forth - kind of arguing, but not really. I have a headache and I don't know why. I also don't know why this nurse is checking me out in the first place. |
|
|
What does your 2017 look like in a Word Cloud? Click on the link and your most frequently used words on FaceBook instantly create a word cloud that speaks of what was most important to you this past year. |
|
|
Highlighted Article of Particular Note this month: Decreased occipital lobe metabolism by FDG-PET/CT An anti–NMDA receptor encephalitis biomarker Objective: To compare brain metabolism patterns on fluorodeoxyglucose (FDG)-PET/CT in anti–NMDA receptor and other definite autoimmune encephalitis (AE) and to assess how these patterns differ between anti–NMDA receptor neurologic disability groups. Conclusions: Marked medial occipital lobe hypometabolism by dedicated brain FDG-PET/CT may serve as an early biomarker for discriminating anti–NMDA receptor encephalitis from other AE. Resolution of lateral and medial occipital hypometabolism may correlate with improved neurologic status in anti–NMDA receptor encephalitis. |
|
|
Decreased occipital lobe metabolism by FDG-PET/CT: An anti-NMDA receptor encephalitis biomarkerAn anti-NMDA receptor encephalitis biomarker John C. Probasco, MD, Lilja Solnes, MD, Abhinav Nalluri, BS, Jesse Cohen, MD, Krystyna M. Jones, MD, Elcin Zan, MD, Mehrbod S. Javadi, MD, and Arun Venkatesan, MD, PhD To compare brain metabolism patterns on fluorodeoxyglucose (FDG)-PET/CT in anti-NMDA receptor and other definite autoimmune encephalitis (AE) and to assess how these patterns differ between anti-NMDA receptor neurologic disability groups. |
|
|
Good news and big strides forward from these 2 pieces of work! The proposed clinical diagnostic criteria for anti-NMDAr encephalitis by Dr. Graus have high sensitivity and specificity in pediatric patients. The median time of fulfilling the criteria in patients with anti-NMDAR was 2 weeks from first symptom onset. Pediatric Neurologists are being directed to this in hospitals around the globe. |
|
|
High sensitivity and specificity in proposed clinical diagnostic criteria for anti‐N‐methyl‐D‐aspartate receptor encephalitisOriginal Article The Children's Hospital at Westmead Clinical School, University of Sydney, Sydney, New South Wales, Australia Neuroimmunology Group, Institute for Neuroscience and Muscle Research, The Children's Hospital at Westmead, Sydney, New South Wales, Australia Department of Paediatrics and Adolescent Medicine, Queen Mary Hospital, The University of Hong Kong, Hong |
|
|
The Mayo Clinic has developed a test, the first of its kind in the United States, that allows doctors to distinguish other inflammatory demyelinating diseases from multiple sclerosis in the early stages of a disorder. In addition to MS, the disorders include optic neuritis, neuromyelitis optica, (NMO), acute disseminated encephalomyelitis, and acute transverse myelitis. The test looks for an antibody against a protein known as myelin oligodendrocyte glycoprotein in the blood. Loss of the protein is associated with inflammatory demyelinating diseases. |
|
|
MS Test Distinguishes Other Demyelinating Diseases from MSThe Mayo Clinic has developed a test that allows doctors to distinguish other inflammatory demyelinating diseases from multiple sclerosis in the early stages of a disorder. The test, the first of its kind in the United States, looks for an antibody against a protein known as myelin oligodendrocyte glycoprotein in the blood. |
|
|
IAES is a 501(c)3 non-profit organization run by volunteers. Your donations allow us to continue to give direct support to people in the AE Community resulting in receiving fast-accurate diagnosis and treatment which saves life. Please consider a charitable tax deductible Donation |
|
|
|
|
